A renal biopsy study of RG-012 Alport patients
Phase of Trial: Phase I/II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs RG 012 (Primary)
- Indications Hereditary nephritis
- Focus Therapeutic Use
- 07 Nov 2017 Status changed from planning to recruiting, according to a Regulus Therapeutics media release.
- 12 May 2017 New trial record
- 04 May 2017 According to a Regulus Therapeutics media release, the company has selected dose for this trial which is expected to commence mid-2017. Data is anticipated by year-end 2017.